Chemotherapy alone for organ preservation in advanced laryngeal cancer

Vasu Divi, Francis P. Worden, Mark E. Prince, Avraham Eisbruch, Julia S. Lee, Carol R. Bradford, Douglas B. Chepeha, Theodoros N. Teknos, Norman D. Hogikyan, Jeffrey S. Moyer, Christina I. Tsien, Susan G. Urba, Gregory T. Wolf

    Research output: Contribution to journalArticlepeer-review

    20 Scopus citations


    Background. For patients with advanced laryngeal cancer, a trial was designed to determine if chemotherapy alone, in patients achieving a complete histologic complete response after a single neoadjuvant cycle, was an effective treatment with less morbidity than concurrent chemoradiotherapy. Methods. Thirty-two patients with advanced laryngeal or hypopharyngeal cancer received 1 cycle of induction chemotherapy, and subsequent treatment was decided based on response. Results. A histologic complete response was achieved in 4 patients and were treated with chemotherapy alone. All 4 patients' cancer relapsed in the neck and required surgery and postoperative radiotherapy (RT). Twenty-five patients were treated with concomitant chemoradiation. Three patients were treated with surgery. Overall survival and disease-specific survival at 3 years were 68% and 78%, respectively. Conclusion. Chemotherapy alone is not feasible for long-term control of regional disease in patients with advanced laryngeal cancer even when they achieve a histologic complete response at the primary site.

    Original languageEnglish
    Pages (from-to)1040-1047
    Number of pages8
    JournalHead and Neck
    Issue number8
    StatePublished - Aug 2010


    • Chemotherapy
    • Clinical outcomes
    • Head and neck neoplasms
    • Laryngeal cancer
    • Organ preservation


    Dive into the research topics of 'Chemotherapy alone for organ preservation in advanced laryngeal cancer'. Together they form a unique fingerprint.

    Cite this